Axon growth inhibition by RhoA/ROCK in the central nervous system

Frontiers in Neuroscience

Volumn 8, Issue OCT, 2014, Pages

  Fujita, Yuki ^a,b   Yamashita, Toshihide ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Axon regeneration; Central nervous system; Myelin; RhoA; ROCK

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BA 210; CSPG PROTEIN; DIMETHYLFASUDIL; FASUDIL; FINGOLIMOD; GELFOAM; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOQUINOLINE DERIVATIVE; MEMBRANE PROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; PROTEIN NOGO; PROTEOGLYCAN; RECOMBINANT PROTEIN; REPULSIVE GUIDANCE MOLECULE A; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; EXPERIMENTAL STROKE; GROWTH INHIBITION; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE INJURY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SPINAL MUSCULAR ATROPHY; T LYMPHOCYTE ACTIVATION; TRAUMATIC BRAIN INJURY;

EID: 84910092956     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00338     Document Type: Review

References (179)

1. Adelson, J. D., Barreto, G. E., Xu, L., Kim, T., Brott, B. K., Ouyang, Y. B., et al. (2012). Neuroprotection from stroke in the absence of MHCI or PirB. Neuron 73, 1100-1107. doi: 10.1016/j.neuron.2012.01.020
2. Anthony, J. C., Breitner, J. C., Zandi, P. P., Meyer, M. R., Jurasova, I., Norton, M. C., et al. (2000). Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066-2071. doi: 10.1212/WNL.54.11.2066
3. Atwal, J. K., Pinkston-Gosse, J., Syken, J., Stawicki, S., Wu, Y., Shatz, C., et al. (2008). PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 322, 967-970. doi: 10.1126/science.1161151
4. Barten, L. J., Allington, D. R., Procacci, K. A., and Rivey, M. P. (2010). New approaches in the management of multiple sclerosis. Drug Des. Devel. Ther. 4, 343-366. doi: 10.2147/DDDT.S9331
5. Barton, W. A., Liu, B. P., Tzvetkova, D., Jeffrey, P. D., Fournier, A. E., Sah, D., et al. (2003). Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J. 22, 3291-3302. doi: 10.1093/emboj/cdg325
6. Bartsch, U., Bandtlow, C. E., Schnell, L., Bartsch, S., Spillmann, A. A., Rubin, B. P., et al. (1995). Lack of evidence that myelin-associated glycoprotein is a major inhibitor of axonal regeneration in the CNS. Neuron 15, 1375-1381. doi: 10.1016/0896-6273(95)90015-2
7. Beher, D., Clarke, E. E., Wrigley, J. D., Martin, A. C., Nadin, A., Churcher, I., et al. (2004). Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 43419-43426. doi: 10.1074/jbc. M404937200
8. Benson, M. D., Romero, M. I., Lush, M. E., Lu, Q. R., Henkemeyer, M., and Parada, L. F. (2005). Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proc. Natl. Acad. Sci. U.S.A. 102, 10694-10699. doi: 10.1073/pnas.0504021102
9. Bertrand, J., Winton, M. J., Rodriguez-Hernandez, N., Campenot, R. B., and McKerracher, L. (2005). Application of Rho antagonist to neuronal cell bodies promotes neurite growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats. J. Neurosci. 25, 1113-1121. doi: 10.1523/JNEUROSCI.3931-04.2005
10. Boato, F., Hendrix, S., Huelsenbeck, S. C., Hofmann, F., Grosse, G., Djalali, S., et al. (2010). C3 peptide enhances recovery from spinal cord injury by improved regenerative growth of descending fiber tracts. J. Cell Sci. 123, 1652-1662. doi: 10.1242/jcs.066050
11. Borisoff, J. F., Chan, C. C., Hiebert, G. W., Oschipok, L., Robertson, G. S., Zamboni, R., et al. (2003). Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol. Cell. Neurosci. 22, 405-416. doi: 10.1016/S1044-7431(02)00032-5
12. Bowerman, M., Beauvais, A., Anderson, C. L., and Kothary, R. (2010). Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum. Mol. Genet. 19, 1468-1478. doi: 10.1093/hmg/ddq021
13. Brabeck, C., Beschorner, R., Conrad, S., Mittelbronn, M., Bekure, K., Meyermann, R., et al. (2004). Lesional expression of RhoA and RhoB following traumatic brain injury in humans. J. Neurotrauma 21, 697-706. doi: 10.1089/0897715041269597
14. Bregman, B. S., Kunkel-Bagden, E., Schnell, L., Dai, H. N., Gao, D., and Schwab, M. E. (1995). Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature 378, 498-501. doi: 10.1038/378498a0
15. Brosamle, C., Huber, A. B., Fiedler, M., Skerra, A., and Schwab, M. E. (2000). Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment. J. Neurosci. 20, 8061-8068.
16. Brown, B. A., Kantesaria, P. P., and McDevitt, L. M. (2007). Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann. Pharmacother. 41, 1660-1668. doi: 10.1345/aph.1G424
17. Cafferty, W. B., Duffy, P., Huebner, E., and Strittmatter, S. M. (2010). MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. J. Neurosci. 30, 6825-6837. doi: 10.1523/JNEUROSCI.6239-09.2010
18. Cafferty, W. B., and Strittmatter, S. M. (2006). The Nogo-Nogo receptor pathway limits a spectrum of adult CNS axonal growth. J. Neurosci. 26, 12242-12250. doi: 10.1523/JNEUROSCI.3827-06.2006
19. Cai, D., Qiu, J., Cao, Z., McAtee, M., Bregman, B. S., and Filbin, M. T. (2001). Neuronal cyclic AMP controls the developmental loss in ability of axons to regenerate. J. Neurosci. 21, 4731-4739.
20. Caroni, P., and Schwab, M. E. (1988). Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1, 85-96. doi: 10.1016/0896-6273(88)90212-7
21. Chastain, E. M., Duncan, D. S., Rodgers, J. M., and Miller, S. D. (2011). The role of antigen presenting cells in multiple sclerosis. Biochim. Biophys. Acta 1812, 265-274. doi: 10.1016/j.bbadis.2010.07.008
22. Chen, H., Lin, Y., Han, M., Bai, S., and Wen, S. (2010). Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. J. Pharm. Biomed. Anal. 52, 242-248. doi: 10.1016/j.jpba.2009.12.028
23. Chen, M. S., Huber, A. B., Van Der Haar, M. E., Frank, M., Schnell, L., Spillmann, A. A., et al. (2000). Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403, 434-439. doi: 10.1038/35000219
24. Chivatakarn, O., Kaneko, S., He, Z., Tessier-Lavigne, M., and Giger, R. J. (2007). The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J. Neurosci. 27, 7117-7124. doi: 10.1523/JNEUROSCI.1541-07.2007
25. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105. doi: 10.1042/0264-6021:3510095
26. Debellard, M. E., Tang, S., Mukhopadhyay, G., Shen, Y. J., and Filbin, M. T. (1996). Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein. Mol. Cell. Neurosci. 7, 89-101. doi: 10.1006/mcne.1996.0007
27. Dergham, P., Ellezam, B., Essagian, C., Avedissian, H., Lubell, W. D., and McKerracher, L. (2002). Rho signaling pathway targeted to promote spinal cord repair. J. Neurosci. 22, 6570-6577.
28. Deyts, C., Galan-Rodriguez, B., Martin, E., Bouveyron, N., Roze, E., Charvin, D., et al. (2009). Dopamine D2 receptor stimulation potentiates PolyQ-Huntingtin-induced mouse striatal neuron dysfunctions via Rho/ROCK-II activation. PLoS ONE 4:e8287. doi: 10.1371/journal.pone.0008287
29. Dickendesher, T. L., Baldwin, K. T., Mironova, Y. A., Koriyama, Y., Raiker, S. J., Askew, K. L., et al. (2012). NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans. Nat. Neurosci. 15, 703-712. doi: 10.1038/nn.3070
30. Dimou, L., Schnell, L., Montani, L., Duncan, C., Simonen, M., Schneider, R., et al. (2006). Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. J. Neurosci. 26, 5591-5603. doi: 10.1523/JNEUROSCI.1103-06.2006
31. Domeniconi, M., Cao, Z., Spencer, T., Sivasankaran, R., Wang, K., Nikulina, E., et al. (2002). Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 35, 283-290. doi: 10.1016/S0896-6273(02)00770-5
32. Dubreuil, C. I., Winton, M. J., and McKerracher, L. (2003). Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162, 233-243. doi: 10.1083/jcb.200301080
33. Endo, T., Spenger, C., Tominaga, T., Brene, S., and Olson, L. (2007). Cortical sensory map rearrangement after spinal cord injury: fMRI responses linked to Nogo signalling. Brain 130, 2951-2961. doi: 10.1093/brain/awm237
34. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., et al. (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449. doi: 10.1172/JCI18162
35. Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., et al. (1990). Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124. doi: 10.1126/science.2111583
36. Fehlings, M. G., Theodore, N., Harrop, J., Maurais, G., Kuntz, C., Shaffrey, C. I., et al. (2011). A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J. Neurotrauma 28, 787-796. doi: 10.1089/neu.2011.1765
37. Filbin, M. T. (2003). Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 4, 703-713. doi: 10.1038/nrn1195
38. Fischer, D., Petkova, V., Thanos, S., and Benowitz, L. I. (2004). Switching mature retinal ganglion cells to a robust growth state in vivo: gene expression and synergy with RhoA inactivation. J. Neurosci. 24, 8726-8740. doi: 10.1523/JNEUROSCI.2774-04.2004
39. Fisher, D., Xing, B., Dill, J., Li, H., Hoang, H. H., Zhao, Z., et al. (2011). Leukocyte common antigen-related phosphatase is a functional receptor for chondroitin sulfate proteoglycan axon growth inhibitors. J. Neurosci. 31, 14051-14066. doi: 10.1523/JNEUROSCI.1737-11.2011
40. Fournier, A. E., Grandpre, T., and Strittmatter, S. M. (2001). Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409, 341-346. doi: 10.1038/35053072
41. Fournier, A. E., Takizawa, B. T., and Strittmatter, S. M. (2003). Rho kinase inhibition enhances axonal regeneration in the injured CNS. J. Neurosci. 23, 1416-1423.
42. Fujita, Y., Endo, S., Takai, T., and Yamashita, T. (2011). Myelin suppresses axon regeneration by PIR-B/SHP-mediated inhibition of Trk activity. EMBO J. 30, 1389-1401. doi: 10.1038/emboj.2011.55
43. Fukata, Y., Itoh, T. J., Kimura, T., Menager, C., Nishimura, T., Shiromizu, T., et al. (2002). CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat. Cell Biol. 4, 583-591. doi: 10.1038/ncb825
44. George, R., and Griffin, J. W. (1994). Delayed macrophage responses and myelin clearance during Wallerian degeneration in the central nervous system: the dorsal radiculotomy model. Exp. Neurol. 129, 225-236. doi: 10.1006/exnr.1994.1164
45. Gil, V., Bichler, Z., Lee, J. K., Seira, O., Llorens, F., Bribian, A., et al. (2010). Developmental expression of the oligodendrocyte myelin glycoprotein in the mouse telencephalon. Cereb. Cortex 20, 1769-1779. doi: 10.1093/cercor/bhp246
46. Grandpre, T., Li, S., and Strittmatter, S. M. (2002). Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417, 547-551. doi: 10.1038/417547a
47. Grandpre, T., Nakamura, F., Vartanian, T., and Strittmatter, S. M. (2000). Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 403, 439-444. doi: 10.1038/35000226
48. Greenwood, J., Walters, C. E., Pryce, G., Kanuga, N., Beraud, E., Baker, D., et al. (2003). Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17, 905-907. doi: 10.1096/fj.02-1014fje
49. Griffin, J. W., George, R., Lobato, C., Tyor, W. R., Yan, L. C., and Glass, J. D. (1992). Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination. J. Neuroimmunol. 40, 153-165. doi: 10.1016/0165-5728(92)90129-9
50. Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S. (2002). Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621-667. doi: 10.1146/annurev.immunol.20.100301.064828
51. Guest, J. D., Hesse, D., Schnell, L., Schwab, M. E., Bunge, M. B., and Bunge, R. P. (1997). Influence of IN-1 antibody and acidic FGF-fibrin glue on the response of injured corticospinal tract axons to human Schwann cell grafts. J. Neurosci. Res. 50, 888-905.
52. Guo, Q., Li, S., and Su, B. (2007). Expression of oligodendrocyte myelin glycoprotein and its receptor NgR after the injury of rat central nervous system. Neurosci. Lett. 422, 103-108. doi: 10.1016/j.neulet.2007.05.034
53. Habib, A. A., Marton, L. S., Allwardt, B., Gulcher, J. R., Mikol, D. D., Hognason, T., et al. (1998). Expression of the oligodendrocyte-myelin glycoprotein by neurons in the mouse central nervous system. J. Neurochem. 70, 1704-1711. doi: 10.1046/j.1471-4159.1998.70041704.x
54. Hara, M., Takayasu, M., Watanabe, K., Noda, A., Takagi, T., Suzuki, Y., et al. (2000). Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J. Neurosurg. 93, 94-101. doi: 10.3171/spi.2000.93.1.0094
55. Harrington, A. W., Li, Q. M., Tep, C., Park, J. B., He, Z., and Yoon, S. O. (2008). The role of Kalirin9 in p75/nogo receptor-mediated RhoA activation in cerebellar granule neurons. J. Biol. Chem. 283, 24690-24697. doi: 10.1074/jbc. M802188200
56. Hata, K., Fujitani, M., Yasuda, Y., Doya, H., Saito, T., Yamagishi, S., et al. (2006). RGMa inhibition promotes axonal growth and recovery after spinal cord injury. J. Cell Biol. 173, 47-58. doi: 10.1083/jcb.200508143
57. Hata, K., Kaibuchi, K., Inagaki, S., and Yamashita, T. (2009). Unc5B associates with LARG to mediate the action of repulsive guidance molecule. J. Cell Biol. 184, 737-750. doi: 10.1083/jcb.200807029
58. Hauser, S. L., and Oksenberg, J. R. (2006). The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52, 61-76. doi: 10.1016/j.neuron.2006.09.011
59. He, Z., and Koprivica, V. (2004). The Nogo signaling pathway for regeneration block. Annu. Rev. Neurosci. 27, 341-368. doi: 10.1146/annurev.neuro.27.070203.144340
60. Hendriks, J. J., Alblas, J., Van Der Pol, S. M., Van Tol, E. A., Dijkstra, C. D., and De Vries, H. E. (2004). Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp. Med. 200, 1667-1672. doi: 10.1084/jem.20040819
61. Hilas, O., Patel, P. N., and Lam, S. (2010). Disease modifying agents for multiple sclerosis. Open Neurol. J. 4, 15-24. doi: 10.2174/1874205X01004010015
62. Hou, S. W., Liu, C. Y., Li, Y. H., Yu, J. Z., Feng, L., Liu, Y. T., et al. (2012). Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. CNS Neurosci. Ther. 18, 909-917. doi: 10.1111/cns.12002
63. Hsieh, S. H., Ferraro, G. B., and Fournier, A. E. (2006). Myelin-associated inhibitors regulate cofilin phosphorylation and neuronal inhibition through LIM kinase and Slingshot phosphatase. J. Neurosci. 26, 1006-1015. doi: 10.1523/JNEUROSCI.2806-05.2006
64. Hu, J. H., Chernoff, K., Pelech, S., and Krieger, C. (2003). Protein kinase and protein phosphatase expression in the central nervous system of G93A mSOD over-expressing mice. J. Neurochem. 85, 422-431. doi: 10.1046/j.1471-4159.2003.01669.x
65. Huber, A. B., Weinmann, O., Brosamle, C., Oertle, T., and Schwab, M. E. (2002). Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J. Neurosci. 22, 3553-3567.
66. Inagaki, N., Chihara, K., Arimura, N., Menager, C., Kawano, Y., Matsuo, N., et al. (2001). CRMP-2 induces axons in cultured hippocampal neurons. Nat. Neurosci. 4, 781-782. doi: 10.1038/90476
67. Ishida, T., Takanashi, Y., and Kiwada, H. (2006). Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol. Pharm. Bull. 29, 397-402. doi: 10.1248/bpb.29.397
68. Ishizaki, T., Uehata, M., Tamechika, I., Keel, J., Nonomura, K., Maekawa, M., et al. (2000). Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57, 976-983.
69. Jaffe, A. B., and Hall, A. (2005). Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21, 247-269. doi: 10.1146/annurev.cellbio.21.020604.150721
70. Ji, B., Case, L. C., Liu, K., Shao, Z., Lee, X., Yang, Z., et al. (2008). Assessment of functional recovery and axonal sprouting in oligodendrocyte-myelin glycoprotein (OMgp) null mice after spinal cord injury. Mol. Cell. Neurosci. 39, 258-267. doi: 10.1016/j.mcn.2008.07.004
71. Johnson, P. W., Abramow-Newerly, W., Seilheimer, B., Sadoul, R., Tropak, M. B., Arquint, M., et al. (1989). Recombinant myelin-associated glycoprotein confers neural adhesion and neurite outgrowth function. Neuron 3, 377-385. doi: 10.1016/0896-6273(89)90262-6
72. Jones, L. L., Margolis, R. U., and Tuszynski, M. H. (2003). The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp. Neurol. 182, 399-411. doi: 10.1016/S0014-4886(03)00087-6
73. Jones, M. V., Nguyen, T. T., Ewaleifoh, O., Lebson, L., Whartenby, K. A., Griffin, J. W., et al. (2013). Accelerated axon loss in MOG35-55 experimental autoimmune encephalomyelitis (EAE) in myelin-associated glycoprotein-deficient (MAGKO) mice. J. Neuroimmunol. 262, 53-61. doi: 10.1016/j.jneuroim.2013.06.008
74. Kassam, A., Nemoto, E., Balzer, J., Rao, G., Welch, W. C., Kuwabara, H., et al. (2004). Effects of Tisseel fibrin glue on the central nervous system of nonhuman primates. Ear. Nose. Throat J. 83, 246-248, 250, 252 passim.
75. Kempf, A., Tews, B., Arzt, M. E., Weinmann, O., Obermair, F. J., Pernet, V., et al. (2014). The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. PLoS Biol. 12:e1001763. doi: 10.1371/journal.pbio.1001763
76. Kim, J. E., Li, S., Grandpre, T., Qiu, D., and Strittmatter, S. M. (2003). Axon regeneration in young adult mice lacking Nogo-A/B. Neuron 38, 187-199. doi: 10.1016/S0896-6273(03)00147-8
77. Kim, J. E., Liu, B. P., Park, J. H., and Strittmatter, S. M. (2004). Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 44, 439-451. doi: 10.1016/j.neuron.2004.10.015
78. Kinter, J., Lazzati, T., Schmid, D., Zeis, T., Erne, B., Lutzelschwab, R., et al. (2012). An essential role of MAG in mediating axon-myelin attachment in Charcot-Marie-Tooth 1A disease. Neurobiol. Dis. 49C, 221-231. doi: 10.1016/j.nbd.2012.08.009
79. Kottis, V., Thibault, P., Mikol, D., Xiao, Z. C., Zhang, R., Dergham, P., et al. (2002). Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth. J. Neurochem. 82, 1566-1569. doi: 10.1046/j.1471-4159.2002.01146.x
80. Krumbholz, M., and Meinl, E. (2014). B cells in MS and NMO: pathogenesis and therapy. Semin. Immunopathol. 36, 339-350. doi: 10.1007/s00281-014-0424-x
81. Kubo, T., Endo, M., Hata, K., Taniguchi, J., Kitajo, K., Tomura, S., et al. (2008). Myosin IIA is required for neurite outgrowth inhibition produced by repulsive guidance molecule. J. Neurochem. 105, 113-126. doi: 10.1111/j.1471-4159.2007.05125.x
82. Kurihara, Y., Arie, Y., Iketani, M., Ito, H., Nishiyama, K., Sato, Y., et al. (2012). The carboxyl-terminal region of Crtac1B/LOTUS acts as a functional domain in endogenous antagonism to Nogo receptor-1. Biochem. Biophys. Res. Commun. 418, 390-395. doi: 10.1016/j.bbrc.2012.01.033
83. Laufs, U., Endres, M., Stagliano, N., Amin-Hanjani, S., Chui, D. S., Yang, S. X., et al. (2000). Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106, 15-24. doi: 10.1172/JCI9639
84. Lauren, J., Airaksinen, M. S., Saarma, M., and Timmusk, T. (2003). Two novel mammalian Nogo receptor homologs differentially expressed in the central and peripheral nervous systems. Mol. Cell. Neurosci. 24, 581-594. doi: 10.1016/S1044-7431(03)00199-4
85. Lee, H., Raiker, S. J., Venkatesh, K., Geary, R., Robak, L. A., Zhang, Y., et al. (2008). Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J. Neurosci. 28, 2753-2765. doi: 10.1523/JNEUROSCI.5586-07.2008
86. Lee, J. K., Geoffroy, C. G., Chan, A. F., Tolentino, K. E., Crawford, M. J., Leal, M. A., et al. (2010). Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron 66, 663-670. doi: 10.1016/j.neuron.2010.05.002
87. Lee, J. K., Kim, J. E., Sivula, M., and Strittmatter, S. M. (2004). Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J. Neurosci. 24, 6209-6217. doi: 10.1523/JNEUROSCI.1643-04.2004
88. Lee, X., Hu, Y., Zhang, Y., Yang, Z., Shao, Z., Qiu, M., et al. (2011). Oligodendrocyte differentiation and myelination defects in OMgp null mice. Mol. Cell. Neurosci. 46, 752-761. doi: 10.1016/j.mcn.2011.02.008
89. Lehmann, M., Fournier, A., Selles-Navarro, I., Dergham, P., Sebok, A., Leclerc, N., et al. (1999). Inactivation of Rho signaling pathway promotes CNS axon regeneration. J. Neurosci. 19, 7537-7547.
90. Li, S., and Strittmatter, S. M. (2003). Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J. Neurosci. 23, 4219-4227.
91. Lingor, P., Teusch, N., Schwarz, K., Mueller, R., Mack, H., Bahr, M., et al. (2007). Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 103, 181-189. doi: 10.1111/j.1471-4159.2007.04756.x
92. Lingor, P., Tonges, L., Pieper, N., Bermel, C., Barski, E., Planchamp, V., et al. (2008). ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 131, 250-263. doi: 10.1093/brain/awm284
93. Liu, B. P., Fournier, A., Grandpre, T., and Strittmatter, S. M. (2002). Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 297, 1190-1193. doi: 10.1126/science.1073031
94. Lord-Fontaine, S., Yang, F., Diep, Q., Dergham, P., Munzer, S., Tremblay, P., et al. (2008). Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J. Neurotrauma 25, 1309-1322. doi: 10.1089/neu.2008.0613
95. Madura, T., Yamashita, T., Kubo, T., Fujitani, M., Hosokawa, K., and Tohyama, M. (2004). Activation of Rho in the injured axons following spinal cord injury. EMBO Rep. 5, 412-417. doi: 10.1038/sj.embor.7400117
96. McGee, A. W., Yang, Y., Fischer, Q. S., Daw, N. W., and Strittmatter, S. M. (2005). Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309, 2222-2226. doi: 10.1126/science.1114362
97. McGeer, P. L., Schulzer, M., and McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432. doi: 10.1212/WNL.47.2.425
98. McKeon, R. J., Jurynec, M. J., and Buck, C. R. (1999). The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J. Neurosci. 19, 10778-10788.
99. McKerracher, L., David, S., Jackson, D. L., Kottis, V., Dunn, R. J., and Braun, P. E. (1994). Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 13, 805-811. doi: 10.1016/0896-6273(94)90247-X
100. Merkler, D., Metz, G. A., Raineteau, O., Dietz, V., Schwab, M. E., and Fouad, K. (2001). Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J. Neurosci. 21, 3665-3673.
101. Mi, S., Lee, X., Shao, Z., Thill, G., Ji, B., Relton, J., et al. (2004). LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci. 7, 221-228. doi: 10.1038/nn1188
102. Mimura, F., Yamagishi, S., Arimura, N., Fujitani, M., Kubo, T., Kaibuchi, K., et al. (2006). Myelin-associated glycoprotein inhibits microtubule assembly by a Rho-kinase-dependent mechanism. J. Biol. Chem. 281, 15970-15979. doi: 10.1074/jbc. M510934200
103. Monnier, P. P., Sierra, A., Schwab, J. M., Henke-Fahle, S., and Mueller, B. K. (2003). The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 22, 319-330. doi: 10.1016/S1044-7431(02)00035-0
104. Moreau-Fauvarque, C., Kumanogoh, A., Camand, E., Jaillard, C., Barbin, G., Boquet, I., et al. (2003). The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J. Neurosci. 23, 9229-9239.
105. Mueller, B. K., Mack, H., and Teusch, N. (2005). Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov. 4, 387-398. doi: 10.1038/nrd1719
106. Mueller, B. K., Yamashita, T., Schaffar, G., and Mueller, R. (2006). The role of repulsive guidance molecules in the embryonic and adult vertebrate central nervous system. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 1513-1529. doi: 10.1098/rstb.2006.1888
107. Mukhopadhyay, G., Doherty, P., Walsh, F. S., Crocker, P. R., and Filbin, M. T. (1994). A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 13, 757-767. doi: 10.1016/0896-6273(94)90042-6
108. Muramatsu, R., Kubo, T., Mori, M., Nakamura, Y., Fujita, Y., Akutsu, T., et al. (2011). RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis. Nat. Med. 17, 488-494. doi: 10.1038/nm.2321
109. Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K., and Narumiya, S. (1996). ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 392, 189-193. doi: 10.1016/0014-5793(96)00811-3
110. Nakajima, E., Nakajima, T., Minagawa, Y., Shearer, T. R., and Azuma, M. (2005). Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J. Pharm. Sci. 94, 701-708. doi: 10.1002/jps.20285
111. Nakamura, H., Matsuyama, Y., Yoshihara, H., Sakai, Y., Katayama, Y., Nakashima, S., et al. (2005). The effect of autologous fibrin tissue adhesive on postoperative cerebrospinal fluid leak in spinal cord surgery: a randomized controlled trial. Spine (Phila Pa 1976) 30, E347-E351. doi: 10.1097/01.brs.0000167820.54413.8e
112. Nakamura, Y., Fujita, Y., Ueno, M., Takai, T., and Yamashita, T. (2011). Paired immunoglobulin-like receptor B knockout does not enhance axonal regeneration or locomotor recovery after spinal cord injury. J. Biol. Chem. 286, 1876-1883. doi: 10.1074/jbc. M110.163493
113. Neuhaus, O., Stuve, O., Zamvil, S. S., and Hartung, H. P. (2004). Are statins a treatment option for multiple sclerosis? Lancet Neurol. 3, 369-371. doi: 10.1016/S1474-4422(04)00770-7
114. Nguyen, T., Mehta, N. R., Conant, K., Kim, K. J., Jones, M., Calabresi, P. A., et al. (2009). Axonal protective effects of the myelin-associated glycoprotein. J. Neurosci. 29, 630-637. doi: 10.1523/JNEUROSCI.5204-08.2009
115. Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., and Weinshenker, B. G. (2000). Multiple sclerosis. N. Engl. J. Med. 343, 938-952. doi: 10.1056/NEJM200009283431307
116. Novotny-Diermayr, V., Lin, B., Gu, L., and Cao, X. (2005). Modulation of the interleukin-6 receptor subunit glycoprotein 130 complex and its signaling by LMO4 interaction. J. Biol. Chem. 280, 12747-12757. doi: 10.1074/jbc. M500175200
117. Ohashi, K., Nagata, K., Maekawa, M., Ishizaki, T., Narumiya, S., and Mizuno, K. (2000). Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275, 3577-3582. doi: 10.1074/jbc.275.5.3577
118. Omoto, S., Ueno, M., Mochio, S., Takai, T., and Yamashita, T. (2010). Genetic deletion of paired immunoglobulin-like receptor B does not promote axonal plasticity or functional recovery after traumatic brain injury. J. Neurosci. 30, 13045-13052. doi: 10.1523/JNEUROSCI.3228-10.2010
119. Park, J. H., Gimbel, D. A., Grandpre, T., Lee, J. K., Kim, J. E., Li, W., et al. (2006). Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J. Neurosci. 26, 1386-1395. doi: 10.1523/JNEUROSCI.3291-05.2006
120. Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., and Gandy, S. (2005). Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med. 2:e18. doi: 10.1371/journal.pmed.0020018
121. Pignot, V., Hein, A. E., Barske, C., Wiessner, C., Walmsley, A. R., Kaupmann, K., et al. (2003). Characterization of two novel proteins, NgRH1 and NgRH2, structurally and biochemically homologous to the Nogo-66 receptor. J. Neurochem. 85, 717-728. doi: 10.1046/j.1471-4159.2003.01710.x
122. Prinjha, R., Moore, S. E., Vinson, M., Blake, S., Morrow, R., Christie, G., et al. (2000). Inhibitor of neurite outgrowth in humans. Nature 403, 383-384. doi: 10.1038/35000287
123. Quarles, R. H. (2007). Myelin-associated glycoprotein (MAG): past, present and beyond. J. Neurochem. 100, 1431-1448. doi: 10.1111/j.1471-4159.2006.04319.x
124. Riento, K., and Ridley, A. J. (2003). Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4, 446-456. doi: 10.1038/nrm1128
125. Rikitake, Y., Kim, H. H., Huang, Z., Seto, M., Yano, K., Asano, T., et al. (2005). Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36, 2251-2257. doi: 10.1161/01.STR.0000181077.84981.11
126. Rosenzweig, E. S., and McDonald, J. W. (2004). Rodent models for treatment of spinal cord injury: research trends and progress toward useful repair. Curr. Opin. Neurol. 17, 121-131. doi: 10.1097/00019052-200404000-00007
127. Sagawa, H., Terasaki, H., Nakamura, M., Ichikawa, M., Yata, T., Tokita, Y., et al. (2007). A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats. Exp. Neurol. 205, 230-240. doi: 10.1016/j.expneurol.2007.02.002
128. Salzer, J. L., Pedraza, L., Brown, M., Struyk, A., Afar, D., and Bell, J. (1990). Structure and function of the myelin-associated glycoproteins. Ann. N.Y. Acad. Sci. 605, 302-312. doi: 10.1111/j.1749-6632.1990.tb42404.x
129. Sasaki, Y., Suzuki, M., and Hidaka, H. (2002). The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol. Ther. 93, 225-232. doi: 10.1016/S0163-7258(02)00191-2
130. Sato, Y., Iketani, M., Kurihara, Y., Yamaguchi, M., Yamashita, N., Nakamura, F., et al. (2011). Cartilage acidic protein-1B (LOTUS), an endogenous Nogo receptor antagonist for axon tract formation. Science 333, 769-773. doi: 10.1126/science.1204144
131. Satoh, S., Utsunomiya, T., Tsurui, K., Kobayashi, T., Ikegaki, I., Sasaki, Y., et al. (2001). Pharmacological profile of hydroxy fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 69, 1441-1453. doi: 10.1016/S0024-3205(01)01229-2
132. Schaffar, G., Taniguchi, J., Brodbeck, T., Meyer, A. H., Schmidt, M., Yamashita, T., et al. (2008). LIM-only protein 4 interacts directly with the repulsive guidance molecule A receptor Neogenin. J. Neurochem. 107, 418-431. doi: 10.1111/j.1471-4159.2008.05621.x
133. Schnell, L., and Schwab, M. E. (1990). Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343, 269-272. doi: 10.1038/343269a0
134. Schwab, J. M., Monnier, P. P., Schluesener, H. J., Conrad, S., Beschorner, R., Chen, L., et al. (2005). Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain. Arch. Neurol. 62, 1561-1568. doi: 10.1001/archneur.62.10.1561
135. Schwab, M. E., and Bartholdi, D. (1996). Degeneration and regeneration of axons in the lesioned spinal cord. Physiol. Rev. 76, 319-370.
136. Shao, J., Welch, W. J., Diprospero, N. A., and Diamond, M. I. (2008). Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell. Biol. 28, 5196-5208. doi: 10.1128/MCB.00079-08
137. Shen, Y., Tenney, A. P., Busch, S. A., Horn, K. P., Cuascut, F. X., Liu, K., et al. (2009). PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 326, 592-596. doi: 10.1126/science.1178310
138. Shimokawa, H. (2002). Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J. Cardiovasc. Pharmacol. 39, 319-327. doi: 10.1097/00005344-200203000-00001
139. Simonen, M., Pedersen, V., Weinmann, O., Schnell, L., Buss, A., Ledermann, B., et al. (2003). Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron 38, 201-211. doi: 10.1016/S0896-6273(03)00226-5
140. Sisodia, S. S., Koo, E. H., Beyreuther, K., Unterbeck, A., and Price, D. L. (1990). Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. Science 248, 492-495. doi: 10.1126/science.1691865
141. Steeves, J. D., Lammertse, D., Curt, A., Fawcett, J. W., Tuszynski, M. H., Ditunno, J. F., et al. (2007). Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 45, 206-221. doi: 10.1038/sj.sc.3102008
142. Sumi, T., Matsumoto, K., and Nakamura, T. (2001). Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 276, 670-676. doi: 10.1074/jbc. M007074200
143. Sun, X., Minohara, M., Kikuchi, H., Ishizu, T., Tanaka, M., Piao, H., et al. (2006). The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 180, 126-134. doi: 10.1016/j.jneuroim.2006.06.027
144. Sung, J. K., Miao, L., Calvert, J. W., Huang, L. Louis Harkey, H., and Zhang, J. H. (2003). A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res. 959, 29-38. doi: 10.1016/S0006-8993(02)03717-4
145. Sunico, C. R., Dominguez, G., Garcia-Verdugo, J. M., Osta, R., Montero, F., and Moreno-Lopez, B. (2011). Reduction in the motoneuron inhibitory/excitatory synaptic ratio in an early-symptomatic mouse model of amyotrophic lateral sclerosis. Brain Pathol. 21, 1-15. doi: 10.1111/j.1750-3639.2010.00417.x
146. Syken, J., Grandpre, T., Kanold, P. O., and Shatz, C. J. (2006). PirB restricts ocular-dominance plasticity in visual cortex. Science 313, 1795-1800. doi: 10.1126/science.1128232
147. Takahashi, Y., Hayashi, I., Tominari, Y., Rikimaru, K., Morohashi, Y., Kan, T., et al. (2003). Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem. 278, 18664-18670. doi: 10.1074/jbc. M301619200
148. Takai, T. (2005). Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 115, 433-440. doi: 10.1111/j.1365-2567.2005.02177.x
149. Tanaka, H., Yamashita, T., Yachi, K., Fujiwara, T., Yoshikawa, H., and Tohyama, M. (2004). Cytoplasmic p21(Cip1/WAF1) enhances axonal regeneration and functional recovery after spinal cord injury in rats. Neuroscience 127, 155-164. doi: 10.1016/j.neuroscience.2004.05.010
150. Tang, X., Davies, J. E., and Davies, S. J. (2003). Changes in distribution, cell associations, and protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenascin-C during acute to chronic maturation of spinal cord scar tissue. J. Neurosci. Res. 71, 427-444. doi: 10.1002/jnr.10523
151. Tokushige, H., Inatani, M., Nemoto, S., Sakaki, H., Katayama, K., Uehata, M., et al. (2007). Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest. Ophthalmol. Vis. Sci. 48, 3216-3222. doi: 10.1167/iovs.05-1617
152. Tompkins, S. M., Padilla, J., Dal Canto, M. C., Ting, J. P., Van Kaer, L., and Miller, S. D. (2002). De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168, 4173-4183. doi: 10.4049/jimmunol.168.8.4173
153. Tonges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, E. M., et al. (2012). Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 135, 3355-3370. doi: 10.1093/brain/aws254
154. Tonges, L., Koch, J. C., Bahr, M., and Lingor, P. (2011). ROCKing regeneration: Rho Kinase inhibition as molecular target for neurorestoration. Front. Mol. Neurosci. 4:39. doi: 10.3389/fnmol.2011.00039
155. Toshima, Y., Satoh, S., Ikegaki, I., and Asano, T. (2000). A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 31, 2245-2250. doi: 10.1161/01.STR.31.9.2245
156. Trapp, B. D., and Nave, K. A. (2008). Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247-269. doi: 10.1146/annurev.neuro.30.051606.094313
157. Turnley, A. M., and Bartlett, P. F. (1998). MAG and MOG enhance neurite outgrowth of embryonic mouse spinal cord neurons. Neuroreport 9, 1987-1990. doi: 10.1097/00001756-199806220-00013
158. Uehata, M., Ishizaki, T., Satoh, H., Ono, T., Kawahara, T., Morishita, T., et al. (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994. doi: 10.1038/40187
159. Venkatesh, K., Chivatakarn, O., Lee, H., Joshi, P. S., Kantor, D. B., Newman, B. A., et al. (2005). The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. J. Neurosci. 25, 808-822. doi: 10.1523/JNEUROSCI.4464-04.2005
160. Walters, C. E., Pryce, G., Hankey, D. J., Sebti, S. M., Hamilton, A. D., Baker, D., et al. (2002). Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J. Immunol. 168, 4087-4094. doi: 10.4049/jimmunol.168.8.4087
161. Wang, K. C., Kim, J. A., Sivasankaran, R., Segal, R., and He, Z. (2002a). P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420, 74-78. doi: 10.1038/nature01176
162. Wang, K. C., Koprivica, V., Kim, J. A., Sivasankaran, R., Guo, Y., Neve, R. L., et al. (2002b). Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 417, 941-944. doi: 10.1038/nature00867
163. Wang, X., Chun, S. J., Treloar, H., Vartanian, T., Greer, C. A., and Strittmatter, S. M. (2002c). Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J. Neurosci. 22, 5505-5515.
164. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216. doi: 10.1038/35102591
165. Wiessner, C., Bareyre, F. M., Allegrini, P. R., Mir, A. K., Frentzel, S., Zurini, M., et al. (2003). Anti-Nogo-A antibody infusion 24 hours after experimental stroke improved behavioral outcome and corticospinal plasticity in normotensive and spontaneously hypertensive rats. J. Cereb. Blood Flow Metab. 23, 154-165. doi: 10.1097/00004647-200302000-00003
166. Wills, Z. P., Mandel-Brehm, C., Mardinly, A. R., McCord, A. E., Giger, R. J., and Greenberg, M. E. (2012). The nogo receptor family restricts synapse number in the developing hippocampus. Neuron 73, 466-481. doi: 10.1016/j.neuron.2011.11.029
167. Wong, S. T., Henley, J. R., Kanning, K. C., Huang, K. H., Bothwell, M., and Poo, M. M. (2002). A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat. Neurosci. 5, 1302-1308. doi: 10.1038/nn975
168. Worter, V., Schweigreiter, R., Kinzel, B., Mueller, M., Barske, C., Bock, G., et al. (2009). Inhibitory activity of myelin-associated glycoprotein on sensory neurons is largely independent of NgR1 and NgR2 and resides within Ig-Like domains 4 and 5. PLoS ONE 4:e5218. doi: 10.1371/journal.pone.0005218
169. Yamashita, T., Higuchi, H., and Tohyama, M. (2002). The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. J. Cell Biol. 157, 565-570. doi: 10.1083/jcb.200202010
170. Yamashita, T., Mueller, B. K., and Hata, K. (2007). Neogenin and repulsive guidance molecule signaling in the central nervous system. Curr. Opin. Neurobiol. 17, 29-34. doi: 10.1016/j.conb.2006.12.001
171. Yamashita, T., and Tohyama, M. (2003). The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci. 6, 461-467. doi: 10.1038/nn1045
172. Yiu, G., and He, Z. (2003). Signaling mechanisms of the myelin inhibitors of axon regeneration. Curr. Opin. Neurobiol. 13, 545-551. doi: 10.1016/j.conb.2003.09.006
173. Yiu, G., and He, Z. (2006). Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 7, 617-627. doi: 10.1038/nrn1956
174. Yu, J. Z., Ding, J., Ma, C. G., Sun, C. H., Sun, Y. F., Lu, C. Z., et al. (2010). Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J. Neurosci. Res. 88, 1664-1672. doi: 10.1002/jnr.22339
175. Zhang, Z., Xu, X., Zhang, Y., Zhou, J., Yu, Z., and He, C. (2009). LINGO-1 interacts with WNK1 to regulate nogo-induced inhibition of neurite extension. J. Biol. Chem. 284, 15717-15728. doi: 10.1074/jbc. M808751200
176. Zheng, B., Atwal, J., Ho, C., Case, L., He, X. L., Garcia, K. C., et al. (2005). Genetic deletion of the Nogo receptor does not reduce neurite inhibition in vitro or promote corticospinal tract regeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 1205-1210. doi: 10.1073/pnas.0409026102
177. Zheng, B., Ho, C., Li, S., Keirstead, H., Steward, O., and Tessier-Lavigne, M. (2003). Lack of enhanced spinal regeneration in Nogo-deficient mice. Neuron 38, 213-224. doi: 10.1016/S0896-6273(03)00225-3
178. Zhou, X., Hu, X., He, W., Tang, X., Shi, Q., Zhang, Z., et al. (2011). Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition. FASEB J. 25, 3146-3156. doi: 10.1096/fj.11-184325
179. Zhou, Y., Su, Y., Li, B., Liu, F., Ryder, J. W., Wu, X., et al. (2003). Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302, 1215-1217. doi: 10.1126/science.1090154